Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

(NasdaqGM:RYTM), — Third quarter 2025 net product revenue from global sales of IMCIVREE(R) (setmelanotide) of $51.3 million — — December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity — — Company is on track to report preliminary results from setmelanotide Phase 2 trial in Prader-Willi syndrome in fourth quarter […]

Ero Announces Result of Year-Long Value-Creation Initiative at Xavantina, Commences First Gold Concentrate Sales in Q4 2025

(TSX:ERO),(NYSE:ERO), VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) — Ero Copper Corp. (TSX: ERO, NYSE: ERO) (“Ero” or the “Company”) is pleased to announce the results of a year-long effort to create additional value from its Xavantina Operations, located in Mato Grosso State, Brazil as well as an update of its National Instrument 43-101

NexGold Achieves Critical Permitting Milestone; Receives Final Federal Approval for the Goldboro Gold Project

(TSX-V:NEXG),(OTC US:NXGCF),(Other OTC:NXGCF), TORONTO, Nov. 04, 2025 (GLOBE NEWSWIRE) — NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company“) is pleased to announce that the Fisheries Act Authorizations (the “FAAs“) for the construction and operation of the Goldboro Gold Project have been granted by Fisheries and Oceans Canada (“DFO“). The FAAs are the

Yukon Metals Launches Digital Marketing Campaign

(CNSX:YMC.CN),(CNSX:YMC),(Boerse Frankfurt – Freiverkehr:E770),(OTC US:YMMCF),(Other OTC:YMMCF), View PDF Version VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company) has entered into a service agreement with Native Ads, Inc. (“Native Ads”) dated October 29, 2025 (the “Agreement”), pursuant to which Native Ads

Chicago Atlantic Real Estate Finance Announces Third Quarter 2025 Financial Results

(NasdaqGM:REFI), CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its results for the quarter ended September 30, 2025. Peter Sack, Co-Chief Executive Officer, noted, “Our loan portfolio and earnings performance this quarter continue to

Woof Gang Advances Fully Integrated Technology Solutions to Give Full Control to the Pet Parents and Drive Tech-Enabled Franchise Growth

MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — Woof Gang Bakery & Grooming (“Woof Gang” or “the Company”), the neighborhood pet grooming and treat boutique, is proud to announce the launch of its first-ever mobile app, delivering a faster, smarter, and more connected experience for pet parents and store owners nationwide. The new app is the

Capital City Bank Appoints Alicia Williams-Ronan Chief Retail Officer

(NASDAQ:CCBG), TALLAHASSEE, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — Capital City Bank today announced that Alicia Williams-Ronan has assumed the role of chief retail officer. She succeeds Randy Lashua, who will retire on December 31 after 20 years of service. In this role, Williams-Ronan will oversee strategy and direct management for all retail sales, service

Verano Holdings Corp. Completes Redomicile of Parent Company from British Columbia to Nevada

(Neo:VRNO.NE),(OTC US:VRNOF),(OtherOTC:VRNOF), CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the completion of its previously announced plan to redomicile Verano Holdings Corp. from British Columbia, Canada, to the State of Nevada. The redomicile was approved by the

Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update

(NasdaqGM:KYMR), Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025 Initiated KT-621 BROADEN2 Phase 2b trial in AD KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 KT-579 (IRF5) IND-enabling studies completed, with Phase 1 clinical

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

(NasdaqGM:MAZE), SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference; fireside chat on Tuesday, November

Scroll to Top